Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 | P51681 | 10/20 | 0.51 |
| ▸ | CXCR4 | P61073 | 2/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 6/20 | 0.47 |
| ▸ | CCR3 | P51677 | 1/20 | 0.43 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.43 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6034645 | 1.00 | CCR5 (0.51) | CCR5CXCR4SIGMAR1CCR3CACNA1G | |
| SCHEMBL6035575 | 0.99 | CCR5 (0.50) | CCR5CXCR4SIGMAR1CCR3CACNA1G | |
| SCHEMBL6034978 | 0.96 | CCR5 (0.47) | CCR5CXCR4SIGMAR1 | |
| SCHEMBL6035554 | 0.93 | CCR5 (0.60) | CCR5CXCR4SIGMAR1 | |
| SCHEMBL6034536 | 0.93 | CCR5 (0.60) | CCR5CXCR4SIGMAR1 | |
| SCHEMBL6033754 | 0.93 | CCR5 (0.49) | CCR5CXCR4SIGMAR1CCR3CACNA1G | |
| SCHEMBL6034896 | 0.93 | CCR5 (0.49) | CCR5CXCR4SIGMAR1CCR3CACNA1G | |
| SCHEMBL6034530 | 0.93 | SIGMAR1 (0.46) | CCR5SIGMAR1CYP2D6TSHRKMT2A | |
| SCHEMBL6034924 | 0.92 | CCR5 (0.59) | CCR5CXCR4SIGMAR1CCR3CACNA1G | |
| SCHEMBL6033734 | 0.92 | CCR5 (0.47) | CCR5CXCR4SIGMAR1CCR3CACNA1G |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060019977-A1 | Spiroheterocyclic derivative compounds and drugs comprising the compound as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-01-26 | — | — | US | claimed |
| EP-1553098-A1 | SPIROHETEROCYCLIC DERIVATIVE COMPOUNDS AND DRUGS COMPRISING THE COMPOUNDS AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-07-13 | — | — | EP | claimed |
| EP-1553098-A1 | SPIROHETEROCYCLIC DERIVATIVE COMPOUNDS AND DRUGS COMPRISING THE COMPOUNDS AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-07-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060019977-A1 | Spiroheterocyclic derivative compounds and drugs comprising the compound as the active ingredient | CCR1, ACKR3, CCR10 | CCR5 7/4885CXCR4 26/4885SIGMAR1 272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.